Avidity Biosciences, Inc.
RNA
$49.77
-$1.00-1.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -455.74M | -369.22M | -322.30M | -280.49M | -252.45M |
| Total Depreciation and Amortization | 3.05M | 2.92M | 2.78M | 2.65M | 2.51M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.29M | 38.44M | 33.21M | 32.83M | 32.36M |
| Change in Net Operating Assets | -81.57M | -27.46M | -14.56M | 60.50M | 61.91M |
| Cash from Operations | -489.98M | -355.32M | -300.87M | -184.50M | -155.67M |
| Capital Expenditure | -12.72M | -9.90M | -7.07M | -4.01M | -3.23M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -191.20M | -654.36M | -847.14M | -734.98M | -284.82M |
| Cash from Investing | -203.91M | -664.27M | -854.20M | -738.99M | -288.06M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 361.90M | 805.00M | 1.05B | 1.07B | 726.71M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -154.00K | 141.40M | 141.40M | 141.40M |
| Cash from Financing | 361.90M | 804.85M | 1.19B | 1.21B | 868.10M |
| Foreign Exchange rate Adjustments | 154.00K | 39.00K | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -331.84M | -214.70M | 37.29M | 287.04M | 424.37M |